X

Aurobindo Pharma Limited Q1FY23; 32% fall in Profits

Revenue for Q1 FY23 has increased by 9% YoY to ₹ 6,235.9 crores. Profits have fallen by 32% YoY to ₹ 520.5 crores because Total Expenses has grown by 17% YoY.

In this quarter’s results, it was visible that revenue growth could not keep up with the drastic increase in expenses.

To further compare this quarter’s results to the past, check out this link.

Related Post